Langhorne, PA-based Alliqua Biomedical in July reported that its exclusive licensing agreement with Summit, NJ-based Celgene Cellular Therapeutics now includes the right to market an advanced wound care product for podiatric and orthopedic applications.
Biovance is a decellularized, dehydrated, human amniotic membrane allograft indicated for management of uninfected partial- and full-thickness wounds, and now, for repair of tendon, nerve, and bone in the foot and ankle.
